Novel Platform Assays for the Diagnosis of Hemostatic Disorders: A Systematic Review

Background: In hemostasis research the novel platform assays for the diagnosis of hemostatic disorders were limited. The purpose of the present review study would be to make a comparison between several assays for assessing the novel hemostatic techniques used in the diagnosis of coagulation disturbance and to point out the most advantageous and disadvantageous aspects of each method as a predictor of morbidity and mortality to determine hemostatic efficacy as well as biological safety. Methods The current systematic review follows the guidelines for observational studies in epidemiology and the PRISMA guidelines. The keywords were used to search the electronic databases (PubMed) (a novel platform to evaluate hemostasis). Searches were restricted to articles published between December 2016 and December 2021; original articles were written in English. To summarize, we collected bibliographies of abstract articles published on a novel platform to evaluate hemostasis studies, Results Following the removal of duplicates, articles were determined by examining the titles and abstracts. Disagreements were resolved through consensus and the application of novel hemostatic analysis methods. The researchers independently reviewed the relevant studies of the recognized records (n = 503), excluding duplicates (n = 9) and irrelevant studies (249). The remaining 254 studies were read in their entirety, and the data from the seven included studies had been extracted Conclusion Nanotechnology-Based Published study formulations discovered it is more optimal for some lab tests when expressed as an anticoagulant for the in vivo evaluation of nanoparticle implications on the complement system, and flow cytometer evaluation could be a promising platform approach for use in hemostasis managers.